Celiac Disease and Elevated Liver Enzymes: A Still Not Fully Defined Pathogenesis

Beenet, Linda; Tonesi, Diego

doi:10.14218/jcth.2021.00074

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of liver enzyme elevation in patients with CD, hypertransaminasemia may be a sign of an associated liver disease or an epiphenomenon, especially at diagnosis and before starting a GFD, when intestinal permeability is increased [18]. As an extraintestinal autoimmune disease sometimes associated with CD, AIH can be a cause of hepatic injury that supports the potential immune-mediated pathogenesis of hypertransaminasemia in celiac patients [18,47]. Antiactin antibodies in CD patients, which show a significant correlation with villous atrophy, also have a very high specificity in AIH [48,49].…”

Section: The Link Between Celiac Disease and Liver Injurymentioning

confidence: 93%

See 1 more Smart Citation

Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease

Cazac,

Mihai,

Ștefănescu

et al. 2024

Nutrients

View full text Add to dashboard Cite

Celiac disease (CD) is a chronic autoimmune disorder triggered by the ingestion of gluten-containing food by genetically predisposed individuals. Hence, treatment of CD consists of permanent avoidance of wheat, rye, barley, and other gluten-containing foods. Lifelong adherence to a gluten-free diet (GFD) improves the symptoms of CD, but recent evidence suggests it is also associated with a higher risk for hepatic steatosis and the coexistence or emergence of other cardiometabolic risk factors. Moreover, a higher risk for liver steatosis is also reported by some authors as a potential extraintestinal complication of the CD itself. Recent nomenclature changes designate the association between hepatic steatosis and at least one of five cardiometabolic risk factors as metabolic dysfunction-associated steatotic liver disease (MASLD). An extended network of potentially causative factors underlying the association between MAFLD and CD, before and after dietary therapy is implemented, was recently described. The individualized treatment of these patients is less supported by evidence, with most of the current recommendations relying on empiric clinical judgment. This review focuses on the causative associations between CD and hepatic injury, either as an extraintestinal manifestation of CD or a side effect of GFD, also referring to potential therapeutic strategies for these individuals.

show abstract

Section: The Link Between Celiac Disease and Liver Injurymentioning

confidence: 93%

“…Antiactin antibodies in CD patients, which show a significant correlation with villous atrophy, also have a very high specificity in AIH [48,49]. Some authors believe it would be helpful to analyze whether these autoantibodies can represent liver damage markers [47].…”

Section: The Link Between Celiac Disease and Liver Injurymentioning

confidence: 99%

Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease

Cazac,

Mihai,

Ștefănescu

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

Liver damage in children and adolescents with newly diagnosed celiac disease: clinical and anamnestic, serological and morphological patterns

Cherkasova¹,

Klimov²,

Kuryaninova³

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Hypertransaminasemia is a common extra-intestinal manifestation of celiac disease. Aim. To analyze the frequency of hypertransaminasemia, clinical and anamnestic, serological and morphological picture in children in the active period of celiac disease. Materials and methods. The study included 272 children with celiac disease aged from 8 months to 17 years. The patients were divided into two groups: the first children with hypertransaminasemia, the second without hypertransaminasemia. Results. Hypertransaminasemia was detected in 55.9% of children with celiac disease. The age of manifestation of the disease in the first group was 1.0 [0.5; 2.0] years, in the second group 1.9 [0.5; 4.0] years (p=0.0004). Children of the first group were diagnosed at 2.5 [1.7; 4.9] years, the second group at 4.9 [3.0; 10.8] years (p0.001). The duration of the latency period in children of the first and second groups was 1.4 [0.6; 3.1] years and 2.4 [0.9; 4.3] years, respectively (p=0.002). The average values of IgA anti-tTG antibodies in children of the analyzed groups did not differ, and the indicators of IgG anti-tTG antibodies in the first group were 1.6 (p=0.04) times higher. The level of EMA in children with hypertransaminasemia was 2 times higher than in children without hypertransaminasemia. Conclusion. Hypertransaminasemia is more often detected in young children with early manifestation of the disease, increases with the deepening of atrophy in the mucous membrane of the small intestine. Higher titers of celiac-specific antibodies were detected in children with hypertransaminasemia.

show abstract

Celiac Disease and Elevated Liver Enzymes: A Still Not Fully Defined Pathogenesis

Cited by 2 publications

References 10 publications

Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease

Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease

Liver damage in children and adolescents with newly diagnosed celiac disease: clinical and anamnestic, serological and morphological patterns

Contact Info

Product

Resources

About